The US Food and Drug Administration (FDA) approves the first self-administered nasal spray flu vaccine.

World

Oscar El Blue

Originally from Tijuana Baja California. Graduate in communication, bilingual announcer and reporter. He specializes in documenting and investigating in a processional manner the issue of immigration and child abuse on the northern borders of Mexico with States as well as the southern border of Tapachula Mexico with Guatemala. Former professional boxer, commentator and analyst of professional boxing fights.

The United States announced on Friday, September 20, 2024, the authorization of the first nasal spray flu vaccine, FluMist, produced by AstraZeneca, which patients will be able to self-administer without the help of health personnel.

FDA has approved FluMist for self-administration or administration by a caregiver; it is approved for the prevention of influenza disease caused by influenza virus subtypes A and B in people 2 to 49 years of age.

Commented Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, “The approval of the first flu vaccine for self-administration or for a caregiver provides a new option to receive a safe and effective seasonal influenza vaccine, potentially with greater convenience, flexibility and accessibility for individuals and families.”

Influenza is a common and contagious respiratory illness caused by a virus that normally circulates in the U.S. during the fall and winter.

The FDA said patients will need a prescription to get FluMist, and that children ages 2 to 17 should not self-administer the vaccine but should receive it from a caregiver.

The nasal spray flu vaccine option is expected to be available in 2025.

Writing: Oscar El Blue

The Food and Drug Administration (FDA)

0 0 votes

Article Rating